RARE Quote, Financials, Valuation and Earnings

Nektar Therapeutics has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of 24.89%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Nektar Therapeutics's return on equity of -133.07%.

Ultragenyx Pharmaceutical has a consensus price target of $91.80, signalling upside risk potential of 141.01%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 534.33%. Given that Nektar Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Nektar Therapeutics is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.607, which suggesting that the stock is 39.255% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.381%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are larger than Nektar Therapeutics quarterly revenues of $29.2M. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Nektar Therapeutics's net income of $7.3M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.15x versus 1.62x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of 24.22%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Ultragenyx Pharmaceutical has a consensus price target of $91.80, signalling upside risk potential of 141.01%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $850.21 which suggests that it could grow by 41.08%. Given that Ultragenyx Pharmaceutical has higher upside potential than Regeneron Pharmaceuticals, analysts believe Ultragenyx Pharmaceutical is more attractive than Regeneron Pharmaceuticals.

Ultragenyx Pharmaceutical has a beta of 0.607, which suggesting that the stock is 39.255% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 15.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.15x versus 4.88x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of -9.24%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Vanda Pharmaceuticals's return on equity of -3.49%.

Ultragenyx Pharmaceutical has a consensus price target of $91.80, signalling upside risk potential of 141.01%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 198.04%. Given that Vanda Pharmaceuticals has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Vanda Pharmaceuticals is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.607, which suggesting that the stock is 39.255% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are larger than Vanda Pharmaceuticals quarterly revenues of $53.2M. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.15x versus 1.24x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Xencor has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of -86.29%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Xencor's return on equity of -35.99%.

Ultragenyx Pharmaceutical has a consensus price target of $91.80, signalling upside risk potential of 141.01%. On the other hand Xencor has an analysts' consensus of $30.30 which suggests that it could grow by 188.3%. Given that Xencor has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Xencor is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.607, which suggesting that the stock is 39.255% less volatile than S&P 500. In comparison Xencor has a beta of 0.900, suggesting its less volatile than the S&P 500 by 10.041%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Xencor pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are larger than Xencor quarterly revenues of $52.8M. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Xencor's net income of -$45.6M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Xencor's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.15x versus 6.19x for Xencor. Usually stocks with elevated PS ratios are considered overvalued.